November 10-15

The official news source of

ACR Convergence 2023

San Diego, CA


Home // Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

//

2 minutes

Esraa Eloseily, MD
Esraa Eloseily, MD

Poster Presenter: Esraa Eloseily, MD, Clinical Fellow in Training, Cincinnati Children’s Hospital Medical Center 

Poster Title: Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

Poster Session A: Sunday, Nov. 12

What is your poster about?
“Lung disease in SJIA is a rare disease complication, and there is limited information on it from prospective, multicenter cohorts. The poster reports the baseline clinical and biochemical characteristics of the SJIA-related lung disease cohort in the CARRA Registry, the largest cohort of children with JIA in North America.”

Why did you decide to investigate this topic?
“SJIA-related lung disease is a life-threatening and increasingly recognized disease complication affecting one in 20 patients with SJIA. However, little is known about disease prevalence, pathogenesis, biomarkers, effect of biologics, and outcomes.”

What are you working on next related to this research?
“We are working on continuing to enroll patients in the registry and to follow up the existing ones to further understand disease course, outcomes, and biomarker profiles in comparison to SJIA patients without lung disease. We also have a rich biosamples collection, including RNA, DNA, plasma, and peripheral blood mononuclear cells, which we hope can accelerate research on SJIA-LD.”

“Understanding the pathogenesis and risk factors of this difficult-to-treat and life-threatening disease will improve our ability to prevent and manage it.”

— Esraa Eloseily, MD

What excites you most about your work?
“Understanding the pathogenesis and risk factors of this difficult-to-treat and life-threatening disease will improve our ability to prevent and manage it.” 

What are you most looking forward to at ACR Convergence 2023 in San Diego?
“I’m excited to network with colleagues from all over the country and the world and to learn about cutting-edge research in the field of pediatric rheumatology!”

WATCH ACR CONVERGENCE 2023 SESSIONS ON DEMAND

If you weren’t able to attend a session in person during ACR Convergence 2023, you haven’t missed out. All registered meeting participants receive on-demand access to scientific sessions through October 31, 2024.